Retraction notice to "Rigosertib potently protects against colitis-associated intestinal fibrosis and inflammation by regulating PI3K/AKT and NF-κB signaling pathways" [Life Sci. 249 (2020) 117470]
Life Sci. 2025 Feb 1:362:123370.
doi: 10.1016/j.lfs.2025.123370.
Epub 2025 Jan 8.
1 Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Iranshahr University of Medical Siences, Iranshahr, Iran.
2 Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
3 Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
4 Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
5 Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
6 Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK.
7 Division of Pulmonary and Critical Care Medicine, Washington University, School of Medicine, Saint Louis, MO, USA.
8 Institute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf 40223, Germany.
9 Cancer Pharmacology Lab, AIRC Start-up, University Hospital of Pisa, Pisa, Italy; Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.
10 Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Finland.
11 Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
12 Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.